FrancophonIA/ELRC3.0 huggingface dataset:
English: During the treatment course in studies with rituximab in combination with chemotherapy, grade 3/4 leucopenia (R-CHOP 88% vs. CHOP 79%, R-FC 23% vs. FC 12%), neutropenia (R-CVP 24% vs. CVP 14%; R-CHOP 97% vs. CHOP 88%, R-FC 30% vs. FC 19% in previously untreated CLL), pancytopenia (R-FC 3% vs. FC 1% in previously untreated CLL) were usually reported with higher frequencies when compared to chemotherapy alone.
Slovenian: Med zdravljenjem v študijah rituksimaba v kombinaciji s kemoterapijo sta bili 3. ali 4. stopnja levkopenije (R-CHOP 88 % v primerjavi s CHOP 79 %, R-FC 23 % v primerjavi s FC 12 %), nevtropenije (R-CVP 24 % v primerjavi s CVP 14 %, R-CHOP 97 % v primerjavi s CHOP 88 %, R-FC: 30 % v primerjavi s FC 19 % pri predhodno nezdravljeni KLL), pancitopenije (R-FC: 3 % v primerjavi s FC 1 % pri predhodno nezdravljeni KLL) po navadi pogostejši kot s kemoterapijo samo.
English: The two adverse events that were reported were flu-like symptoms, with a dose of 1.8 g of rituximab and fatal respiratory failure, with a dose of 2 g of rituximab.
Slovenian: Dva opisana neželena dogodka sta bila gripi podobni simptomi (pri odmerku 1,8 g rituksimaba) in odpoved dihal s smrtnim izidom (pri odmerku 2 g
English: A slight but not significant improvement in overall survival was reported in the R-FC
Slovenian: Poročali so o rahlem, vendar ne pomembnem izboljšanju celokupnega preživetja v skupini
English: CLL affects B-lymphocytes, which originate in the bone marrow and develop in the lymph nodes.
Slovenian: Prizadene limfocite B, ki nastajajo v kostnem mozgu in se razvijajo v limfnih vozličih.
English: Concomitant/sequential use of other DMARDs in rheumatoid arthritis The concomitant use of rituximab and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
Slovenian: Sočasna/zaporedna uporaba drugih DMARD pri revmatoidnem artritisu Sočasna uporaba rituksimaba in zdravil za zdravljenje revmatičnih bolezni, razen omenjenih v indikaciji in odmerjanju za revmatoidni artritis, ni priporočljiva.
English: Less frequently, some patients may get pain at the infusion site, blisters, itching, sickness, tiredness, headache, breathing difficulties, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets.
Slovenian: Manj pogosto se lahko pri nekaterih bolnikih pojavijo bolečina na mestu infundiranja, mehurji, srbenje, slabost, utrujenost, glavobol, težave z dihanjem, otekanje jezika ali grla, srbeč ali smrkav nos, bruhanje, pordevanje ali hitro in močno utripanje srca, srčna kap ali nizko število trombocitov.
English: 1 Frequency category derived from laboratory values collected as part of routine laboratory monitoring in clinical trials 2 Frequency category derived from post-marketing data.
Slovenian: 1Pogostnost pridobljena iz laboratorijskih vrednosti zbranih v okviru rutinskega laboratorijskega spremljanja v kliničnih
English: Response rate and CR rates analysed using Chi-squared Test. NR: not reached n.a. not applicable *: only applicable to patients achieving a CR, nPR, PR; **: only applicable to patients achieving a CR;
Slovenian: NR: nedoseženo; n.a. neaplikabilno *: aplikabilno samo za bolnike, ki so dosegli CR, nPR (nodularni delni odgovor), PR; **: aplikabilno samo za bolnike, ki so dosegli CR
English: Rituzena should be administered on day 1 of each chemotherapy cycle, after intravenous administration of the glucocorticoid component of the chemotherapy if applicable.
Slovenian: Zdravilo Rituzena je treba dajati prvi dan vsakega cikla kemoterapije po uporabi glukokortikoidne sestavine kemoterapije, če jo shema vsebuje.
English: 95.1%b CI (−3.2%, 24.3%) a a Non-inferiority was demonstrated since the lower bound (−3.2%) was higher than the pre-determined b The 95.1% confidence level reflects an additional 0.001 alpha to account for an interim efficacy analysis.
Slovenian: 95,1 %b IZ (−3,2 %, 24,3 %) a a Neinferiornost je bila dokazana, ker je bila spodnja meja (−3,2 %) višja od vnaprej opredeljene meje neinferiornosti (−20 %).
English: Corticosteroid medicine given by mouth may be started at any time by your doctor to treat your condition.
Slovenian: Zdravilo s kortikosteroidom, ki ga boste uživali, pa vam zdravnik lahko za zdravljenje vaše
English: In case of such an event with a suspected relationship to rituximab, treatment should be permanently discontinued.
Slovenian: Če se pojavi tak neželen učinek z možno povezavo z rituksimabom, je treba zdravljenje trajno ukiniti.
English: Summary of the safety profile (non-Hodgkin's lymphoma and chronic lymphocytic leukaemia)
Slovenian: Povzetek varnostnega profila (ne-Hodgkinov limfom in kronična limfocitna levkemija)
English: severe bullous skin reactions, Stevens-Johns on Syndrome toxic epidermal necrolysis (Lyell's Syndrome)7,
Slovenian: hude bulozne kožne reakcije, StevensJohnsonov sindrom, toksična epidermalna nekroliza (Lyellov sindrom)7
English: In the clinical trial evaluating rituximab maintenance treatment in relapsed/refractory follicular lymphoma, median IgG levels were below the lower limit of normal (LLN) (<7 g/L) after induction treatment in both the observation and the rituximab groups.
Slovenian: V kliničnem preskušanju za oceno vzdrževalnega zdravljenja z rituksimabom pri ponovitvi folikularnih limfomov ali neodzivni bolezni je bila mediana koncentracije IgG po indukcijskem zdravljenju pod spodnjo mejo normalne vrednosti (SMN) (< 7 g/L) tako v opazovani skupini kot v skupini z rituksimabom.
English: Rituximab infusions were administered after an intravenous infusion of 100 mg methylprednisolone; patients also received treatment with oral prednisone for 15 days.
Slovenian: Infuzija rituksimaba je sledila intravenski infuziji 100 mg metilprednizolona; bolniki so 15 dni tudi
English: From month 12 to month 18, 8 relapses were observed in the rituximab group compared with four in the cyclophosphamide group.
Slovenian: Od 12. do 18. meseca so v skupini z rituksimabom zabeležili 8 ponovitev in v
English: Also do not breast-feed for 12 months after your last treatment with Rituzena.
Slovenian: Prav tako ne smete dojiti še 12 mesecev po zadnjem odmerku zdravila Rituzena.
English: Ninety nine patients were treated with rituximab and 12% experienced at least one IRR.
Slovenian: Z rituksimabom se je zdravilo 99 bolnikov in pri 12 % bolnikov se je pojavila vsaj ena reakcija, povezane z infuzijo.
English: The clinical relevance of HACA formation in rituximab-treated patients is unclear.
Slovenian: Klinični pomen pojava HACA pri bolnikih, zdravljenih z rituksimabom, ni
English: In patients with granulomatosis with polyangiitis or microscopic polyangiitis, the number of peripheral blood B cells decreased to <10 cells/μL after two weekly infusions of rituximab 375 mg/m2, and remained at that level in most patients up to the 6 month time point.
Slovenian: Pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom se je število perifernih celic B zmanjšalo na < 10 celic/µl po dveh infundiranjih 375 mg/m2 rituksimaba (po enem na teden) in je na tej ravni ostalo do 6 mesecev.
English: Occurred at various times up to several months after completion of rituximab
Slovenian: Pojavili so se različno, tudi do nekaj mesecev po končanem zdravljenju z
English: Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with rituximab.
Slovenian: Pri vseh bolnikih je treba pred začetkom zdravljenja z rituksimabom narediti presejalni test na virus hepatitisa B (HBV).
English: Subsequent doses of Rituzena can be infused at an initial rate of 100 mg/h, and increased by 100 mg/h increments at 30 minute intervals, to a maximum of 400 mg/h.
Slovenian: Nadaljnje odmerke zdravila Rituzena lahko dajemo z začetno hitrostjo 100 mg/h, ki jo lahko vsakih 30 minut povečujemo po 100 mg/h, dokler ne dosežemo največje hitrosti infundiranja 400 mg/h.
English: The complete response rate after cycle 8 was 76.2 % in the R-CHOP group and 62.4 % in the CHOP
Slovenian: Po 8 ciklih zdravljenja je bil popolni odgovor v skupini R-CHOP 76,2 %, v skupini CHOP pa 62,4 % (p = 0,0028).
English: • Detailed information on the risk of PML, the need for timely diagnosis of PML
Slovenian: • podrobne podatke o tveganju za PML, informacije o nujnosti njene pravočasne diagnoze in ustreznih ukrepov za diagnosticiranje te bolezni,
English: • If you are having Rituzena with chemotherapy Rituzena will be given to you on the same day as your chemotherapy.
Slovenian: Če prejemate zdravilo Rituzena skupaj s kemoterapijo, ga boste dobili isti dan kot kemoterapijo.
English: The consequences of long-term B cell depletion in paediatric
Slovenian: Posledice dolgotrajnega zmanjšanja števila celic B pri
English: If any doubt exists, further evaluation, including MRI scan preferably with contrast, cerebrospinal fluid (CSF) testing for JC Viral DNA and repeat neurological assessments, should be considered.
Slovenian: V primeru dvoma je smiselno nadaljnje ovrednotenje, vključno z magnetnoresonančno preiskavo (MR), po možnosti s kontrastom, določanjem prisotnosti DNK virusa JC v cerebrospinalni tekočini in ponovno
English: In the 99 rituximab patients, the overall rate of infection was approximately 237 per 100 patient years (95% CI 197-285) at the 6-month primary endpoint.
Slovenian: Med 99 bolniki, ki so prejeli rituksimab, je bil celotni delež okužb na primarni končni točki po 6 mesecih približno 237 na 100 bolnik-let (95-% interval zaupanja, 197-285).
English: Medicinal products for the treatment of hypersensitivity reactions, e.g., epinephrine (adrenaline), antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of rituximab.
Slovenian: Zdravila za zdravljenje reakcij preobčutljivosti, npr. adrenalin, antihistaminiki in glukokortikoidi, morajo biti na voljo za takojšnjo uporabo, če bi se med dajanjem rituksimaba pojavile alergijske reakcije.
English: In a non-randomised study, patients with relapsed low-grade NHL who received rituximab monotherapy when compared to healthy untreated controls had a lower rate of response to vaccination with tetanus recall antigen (16% vs. 81%) and Keyhole Limpet Haemocyanin (KLH) neoantigen (4% vs. 76% when assessed for >2-fold increase in antibody titer).
Slovenian: V nerandomizirani študiji so imeli bolniki, ki so prejeli samostojno zdravljenje z rituksimabom ob ponovitvi nizkomalignega NHL, v primerjavi z zdravimi kontrolnimi osebami, ki niso prejele zdravila, nižji delež odgovora na cepljenje s cepivom proti tetanusu (recall antigen) (16 % v primerjavi z 81 %) in neoantigenom KLH (Keyhole Limpet Haemocyanin) (4 % v primerjavi s 76 %, ko so določevali > 2
English: Of 356 patients evaluated for HACA, 1.1 % (4 patients) were positive.
Slovenian: Od 356 bolnikov, pri katerih so ocenjevali HACA, so bili pozitivni
English: R-FC (N=408)
Slovenian: FC (n = 409)
English: Package leaflet: Information for the patient Rituzena 100 mg concentrate for solution for infusion rituximab This medicine is subject to additional monitoring.
Slovenian: Navodilo za uporabo Rituzena 100 mg koncentrat za raztopino za infundiranje rituksimab Za to zdravilo se izvaja dodatno spremljanje varnosti.
English: Signs and symptoms included visual disturbance, headache, seizures and altered mental status, with or without associated hypertension.
Slovenian: Med znaki in simptomi so bili motnje vida, glavobol, konvulzije in motnje zavesti s spremljajočo hipertenzijo ali brez nje.
English: Rituzena can be given alone or with other medicines called “chemotherapy”.
Slovenian: Zdravilo Rituzena lahko uporabljamo samostojno ali skupaj z drugimi zdravili, ki jih imenujemo
English: The incidence of malignancy in rituximab treated patients in the granulomatosis with polyangiitis and microscopic polyangiitis clinical study was 2.00 per 100 patient years at the study common closing date (when the final patient had completed the follow-up period).
Slovenian: Incidenca malignih bolezni med bolniki, ki so v klinični študiji pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom prejemali rituksimab, je bila ob končnem zaključnem datumu študije (tj. ko je zadnji bolnik dokončal obdobje spremljanja) 2,00 na 100 bolnik-let.
English: Physicians should review the patient's vaccination status and follow current immunisation guidelines prior to rituximab therapy.
Slovenian: Zdravniki morajo pred zdravljenjem z rituksimabom pregledati status cepljenja bolnikov in upoštevati veljavne smernice za cepljenje.
English: Repeated treatment courses
Slovenian: Večkratno zdravljenje
English: In patients with relapsed/refractory CLL, the incidence of grade 3/4 hepatitis B infection (reactivation and primary infection) was 2% in R-FC vs 0% FC.
Slovenian: Pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, je bila incidenca okužbe s hepatitisom B stopnje 3 ali 4 (reaktivacija in primarna okužba) 2 % pri R-FC v primerjavi z 0 % pri FC (fludarabin in ciklofosfamid).
English: Progression‐free survival (PFS)
Slovenian: EFS: preživetje brez dogodka (Event Free Survival)
English: • memory loss, trouble thinking, difficulty walking or sight loss - these may be due to a very rare,
Slovenian: • poslabšanje spomina, motnje mišljenja, težave s hojo ali izguba vida - lahko so posledica zelo redke, resne okužbe možganov, ki je včasih smrtna (imenujemo jo progresivna multifokalna
English: Since hypotension may occur during rituximab infusion, consideration should be given to withholding anti-hypertensive medicinal product 12 hours prior to the rituximab infusion.
Slovenian: Ker se med infuzijo rituksimaba lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred infuzijo rituksimaba bolnik prenehal jemati zdravila proti
English: The pharmacokinetics of rituximab were assessed following two IV doses of 500 mg and 1000 mg upon re-treatment in the second course.
Slovenian: Farmakokinetiko rituksimaba so ocenili po dveh 500 mg in 1.000 mg intravenskih odmerkih pri ponovnem zdravljenju v drugem ciklu.
English: The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p <
Slovenian: Mediano trajanje odgovora je bilo 37,7 meseca v skupini z R-CVP in 13,5 meseca v skupini s CVP (p < 0,0001, log-rang test).
English: • low number of white blood cells sometimes with fever, or low number of blood cells called
Slovenian: majhno število belih krvnih celic, včasih z zvišano telesno temperaturo, ali zmanjšanje števila krvnih celic, ki jih imenujemo trombociti (krvne ploščice),
English: Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients listed in
Slovenian: Preobčutljivost za zdravilno učinkovino ali mišje beljakovine ali na katero koli drugo pomožno snov,
English: If the same severe adverse reactions occur for a second time, the decision to stop the treatment should be seriously considered on a case by case basis.
Slovenian: Če ponovno pride do enakih hudih neželenih reakcij, razmislimo o ukinitvi zdravljenja.
English: Studies in previously untreated and relapsed/refractory CLL have established that in up to 25% of patients treated with R-FC neutropenia was prolonged (defined as neutrophil count remaining below 1x109/L between day 24 and 42 after the last dose) or occurred with a late onset (defined as neutrophil count below 1x109/L later than 42 days after last dose in patients with no previous prolonged neutropenia or who recovered prior to day 42) following treatment with rituximab plus FC.
Slovenian: V študijah pri bolnikih s KLL, ki še niso bili zdravljeni in pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, so ocenili, da je bila pri največ 25 % bolnikov zdravljenih z R-FC nevtropenija podaljšana (opredeljena kot število nevtrofilcev, ki med dnevoma 24 in 42 po zadnjem prejetem odmerku ostane pod 1x109/l) ali pa se je po zdravljenju z rituksimabom in FC pojavila kasneje (opredeljena kot število nevtrofilcev pod 1x109/l po 42. dnevu od zadnjega prejetega odmerka pri bolnikih, ki niso imeli podaljšane nevtropenije ali pa so si opomogli pred dnevom 42).
English: • The active ingredient in Rituzena is called rituximab.
Slovenian: • Zdravilna učinkovina zdravila Rituzena je rituksimab.
English: The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1% after
Slovenian: Incidenca simptomov, povezanih z infuzijo, se z nadaljnjimi infuzijami bistveno zmanjšuje in je po osmih odmerkih rituksimaba manjša kot 1 %.
English: PML, reactivation of hepatitis B late neutropenia2 serum sicknesslike reaction
Slovenian: PML, reaktivacija hepatitisa B
English: Summary of the Safety Profile (granulomatosis with polyangiitis and microscopic polyangiitis) In the clinical trial in granulomatosis with polyangiitis and microscopic polyangitis, 99 patients were treated with rituximab (375 mg/m2, once weekly for 4 weeks) and glucocorticoids (see section 5.1).
Slovenian: Povzetek varnostnega profila (granulomatoza s poliangiitisom in mikroskopski poliangiitis) V klinični študiji pri granulomatozi s poliangiitisom in mikroskopskem poliangiitisu so 99 bolnikov zdravili z rituksimabom (375 mg/m2 enkrat na teden 4 tedne) in z glukokortikoidi (glejte poglavje 5.1).
English: In most cases, the infusion can be resumed at a 50 % reduction in rate (e.g. from 100 mg/h to 50 mg/h) when symptoms have completely
Slovenian: Ko se simptomi popolnoma izboljšajo, lahko pri večini primerov infuzijo nadaljujemo s polovično hitrostjo infundiranja (npr. s 100 mg/h na 50 mg/h).
English: A total of 23/99 (23%) rituximab-treated patients in the trial tested positive for HACA by 18 months.
Slovenian: Do 18. meseca je imelo pozitiven izvid HACA skupno 23 od 99 (23 %) bolnikov, ki so bili v preskušanju zdravljeni z rituksimabom.
English: Contraindications for use in rheumatoid arthritis, granulomatosis with polyangiitis and microscopic
Slovenian: Kontraindikacije za uporabo pri revmatoidnem artritisu, granulomatozi s poliangiitisom in
English: Rituzena is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
Slovenian: Zdravilo Rituzena je indicirano za zdravljenje predhodno nezdravljenih bolnikov s III. in IV. stadijem folikularnih limfomov v kombinaciji s kemoterapijo.
English: Patients were randomised in a 1:1 ratio to receive either oral cyclophosphamide daily (2mg/kg/day) for 3-6 months or rituximab (375 mg/m2) once weekly for 4 weeks.
Slovenian: Bolnike so v razmerju 1:1 randomizirali na zdravljenje s peroralnim ciklofosfamidom (2 mg/kg/dan) vsak dan od 3 do 6 mesecev ali z rituksimabom (375 mg/m2) enkrat na teden 4 tedne.
English: This is because Rituzena can affect the way some other medicines work.
Slovenian: Zdravilo Rituzena namreč lahko vpliva na delovanje nekaterih drugih zdravil in obratno - tudi nekatera druga zdravila lahko vplivajo na delovanje zdravila Rituzena.
English: Table 2 Summary of adverse drug reactions reported in clinical trials or during post marketing surveillance occurring in patients with rheumatoid arthritis receiving
Slovenian: Povzetek neželenih učinkov, o katerih so poročali med kliničnimi študijami ali po prihodu zdravila na trg pri bolnikih z revmatoidnim artritisom, ki so prejemali rituksimab.
English: The prepared Rituzena solution should be administered as an intravenous infusion through a dedicated line.
Slovenian: Pripravljeno raztopino zdravila Rituzena dajemo kot intravensko infuzijo skozi poseben kanal.
English: Therefore, in patients with a known cardiac history, and those who experienced prior cardiopulmonary adverse reactions the risk of cardiovascular complications resulting from infusion reactions should be considered before treatment with rituximab and patients closely monitored during administration.
Slovenian: pri katerih so v preteklosti opazili kardio-pulmonalne neželene učinke, razmisliti o možnih kardiovaskularnih zapletih, ki lahko nastanejo kot posledica reakcij, povezanih z infuzijo, bolnike pa med dajanjem zdravila skrbno nadzorovati.
English: Physicians should exercise caution when considering the use of rituximab in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see section 4.8).
Slovenian: Pri odločanju za uporabo rituksimaba morajo biti zdravniki previdni pri bolnikih z anamnezo ponavljajočih se ali kroničnih okužb ali s sočasnimi boleznimi, zaradi katerih so lahko bolniki dodatno nagnjeni k resnim okužbam (glejte poglavje 4.8).
English: The recommended dosage of Rituzena for induction of remission therapy of granulomatosis with polyangiitis and microscopic polyangiitis is 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (four infusions in total).
Slovenian: Priporočeno odmerjanje zdravila Rituzena za indukcijo remisije pri zdravljenju granulomatoze s poliangiitisom in mikroskopskega poliangiitisa je 375 mg/m2 telesne površine v intravenski infuziji 1-krat na teden 4 tedne (skupaj štiri infuzije).
English: The Patient information about Rituzena should contain the following key elements:
Slovenian: Gradivo za bolnika o zdravilu Rituzena mora vsebovati naslednje ključne vsebine:
English: This is a disease of the lymph tissue (part of the immune system) that affects B-Lymphocytes.
Slovenian: Ne-Hodgkinov limfom je bolezen limfatičnega tkiva (ta je del imunskega sistema), ki prizadene
English: The most frequent ADRs following receipt of rituximab in clinical studies were IRRs.
Slovenian: Najpogostejši neželeni učinki po prejemu rituksimaba v kliničnih preskušanjih so bile reakcije, povezane z infuzijo.
English: The Physician information about Rituzena should contain the following key elements:
Slovenian: Gradivo za zdravnika o zdravilu Rituzena mora vsebovati naslednje ključne vsebine:
English: lung infiltration gastro-intestin al perforation7
Slovenian: odpoved dihal4 infiltracija pljuč perforacija prebavil7
English: The chemotherapy should be given after Rituzena infusion.
Slovenian: Kemoterapijo boste dobili po infuziji zdravila Rituzena.
English: Serious infections, including fatalities, can occur during therapy with rituximab (see section 4.8).Rituximab should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3) or severely immunocompromised patients (e.g. where levels of CD4 or CD8 are very low).
Slovenian: Rituksimaba se ne sme dajati bolnikom z aktivno, hudo okužbo (npr. tuberkulozo, sepso ali oportunističnimi okužbami, glejte poglavje 4.3) ali hudo imunokompromitiranim bolnikom (npr. pri zelo nizkih vrednostih CD4 ali CD8).
English: Cardiac events were reported as serious adverse events (including atrial fibrillation, myocardial infarction, left ventricular failure, myocardial ischaemia) in 3% of patients treated with rituximab compared to <1% on observation.
Slovenian: O resnih neželenih dogodkih, povezanih s srcem (vključno z atrijsko fibrilacijo, miokardnim infarktom, popuščanjem levega prekata, ishemijo miokarda), so poročali pri 3 % bolnikov, ki so prejemali rituksimab in pri manj kot 1 % bolnikov v opazovani skupini.
English: How much and how often you will receive your treatment d) If you are being treated for non-Hodgkin's Lymphoma
Slovenian: Koliko zdravila boste dobili in kako pogosto a) Če se zdravite zaradi ne-Hodgkinovega limfoma ga boste prejeli enkrat na teden 4 tedne.
English: Reactions attributed to hypersensitivity have been reported less frequently than those attributed to cytokine release.
Slovenian: O preobčutljivostnih reakcijah so poročali redkeje kot o reakcijah